Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma:a multi-center propensity score matched analysis of real-world practice  

作　　者：Shaohua Li Jie Mei Qiaoxuan Wang Feng Shi Hongyan Liu Ming Zhao Lianghe Lu Yihong Ling Zhixing Guo Yabing Guo Xiaoming Chen Ming Shi Wan Yee Lau Wei Wei Rongping Guo 

机构地区：[1]Department of Liver Surgery,Sun Yat-sen University Cancer Center,Guangzhou,China [2]State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou,China [3]Department of Radiation Oncology,Sun Yat-sen University Cancer Center,Guangzhou,China [4]Department of Interventional Radiology,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China [5]State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou,China [6]Department of Interventional Radiology,Sun Yat-sen University Cancer Center,Guangzhou,China [7]Department of Pathology,Sun Yat-sen University Cancer Center,Guangzhou,China [8]Department of Ultrasound,Sun Yat-sen University Cancer Center,Guangzhou,China [9]Faculty of Medicine,the Chinese University of Hong Kong,Shatin,New Territories,Hong Kong,China

出　　处：《Hepatobiliary Surgery and Nutrition》2021年第5期631-645,I0009-I0016,共23页肝胆外科与营养（英文）

基　　金：This study was supported by the National Natural Science Foundation of China(No.81871985);Natural Science Foundation of Guangdong Province(No.2018A0303130098 and No.2017A030310203);Science and Technology Planning Project of Guangdong Province(No.2017A020215112);Medical Scientific Research Foundation of Guangdong Province(No.A2017477);Science and Technology Planning Project of Guangzhou(No.201903010017 and No.201904010479);Clinical Trials Project(5010 Project)of Sun Yat-sen University(No.5010-2017009);and Clinical Trials Project(308 Project)of Sun Yat-sen University Cancer Center(No.308-2015-014).

摘　　要：Background:To compare the treatment effectiveness and safety among transarterial infusion chemotherapy(TAI)with FOLFOX regimen,transarterial chemoembolization(TACE),and sorafenib in patients with BCLC stage C hepatocellular carcinoma(HCC).Methods:The data of consecutive patients with BCLC stage C HCC treated with TAI,TACE,or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed.Propensity-score matched(PSM)analysis was pairwise performed to reduce selection bias.Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method,log-rank test,Cox regression models,andχ2 test.Results:The median overall survival(OS)in the matched TAI cohort was significantly longer than the sorafenib cohort(19.6 vs.7.5 months,P=0.009),and the TACE cohort(estimated 27.8 vs.6.6 months,P<0.001).The difference in median progression-free survival(PFS)between the matched TAI and sorafenib cohorts was not significant(5.8 vs.2.3 months,P=0.219).The median PFS in the matched TAI cohort was significantly longer than the TACE cohort(6.5 vs.2.8 months,P<0.001).The objective response rate(ORR)in the matched TAI cohort was significantly higher than the sorafenib cohort(36.4%vs.0.0%,P<0.001)and the TACE cohort(48.7%vs.4.7%,P<0.001).The incidences of adverse events(AEs)were similar among these three cohorts.Conclusions:TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC.

关 键 词：Hepatocellular carcinoma(HCC) transarterial infusion chemotherapy SORAFENIB transarterial chemoembolization FOLFOX 

分 类 号：R73[医药卫生—肿瘤]